The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Filter
Locations
Result types
Type of company
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Lock keywords
Exclude keywords
Optional keywords
San Cibrao das Viñas, Spain
1-10 Employees
2022
Invest in Aptadegrad, a great opportunity to create value with rapid development of new compounds. Non-biological manufacturing of both the chemical degraders and the warheads avoids high costs and greatly reduces logistics constraints. We would be delighted to show you the advantages and benefits that Aptadegrad can provide you.
+
Featured
A flexible, cost-effective, targeted protein degradation platform.
... A targeted protein degradation platform based on the combination of an aptamer and a degrader that harnesses protein degradation pathways within the cells. ...
London, United Kingdom
51-100 Employees
2015
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals, tracking targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development. In partnership with the world’s leading drug development experts to help you keep up with the pace of preclinical and clinical research developments. Each Beacon Solution is designed specifically to focus on one therapeutic class. Beacon Cancer Vaccine provides the solution you need to master the prophylactic and therapeutic cancer vaccines field. From gene-editing technologies, novel delivery systems, and a variety of genetic materials being used – Beacon Gene Therapy steps into the field to give drug developers a precise and detailed view of how the gene therapy landscape looks. Covering all therapeutics aimed at treating immune-mediated diseases – Beacon Immune Tolerance provides drug developers with detailed views of the expanding immune tolerance landscape. Covering all pharmaceutical grade microbiome-based therapeutics across all disease indications – Beacon Microbiome provides drug developers with detailed views of the expanding microbiome landscape. Beacon TPD provides the solution you need to master the targeted protein degradation field.
+
Featured
Beacon - Targeted Protein Degradation Database - Make faster and better informed drug development decisions
... Beacon Targeted Protein Degradation (TPD) covers trial and drug records for clinical, preclinical, approved and discontinued therapeutics involved in targeted protein degradation. ...
London, United Kingdom
1-10 Employees
Whilst continuing to deliver breaking clinical updates first and foremost from the field’s key players; Nurix Therapeutics, C4 Therapeutics, Foghorn Therapeutics, Arvinas, and Kymera Therapeutics, the summit also featured an additional discovery track, to cater for and support the rapidly expanding network of early-stage developers in the field.
+
Featured
6th Targeted Protein Degradation Summit
... The 6th TPD Summit returns to Boston as the most comprehensive, definitive and trusted forum for the global network of protein degradation experts. ...
Copenhagen, Denmark
11-50 Employees
2017
Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society. We are establishing ourselves at the forefront of protein degradation. At Draupnir, our differentiated platform technology is enabling the development of protein degraders that target extracellular disease proteins, with potential to target 40% of the human proteome and offering broad disease applicability across multiple areas of unmet therapeutic need. Our team at Draupnir Bio is driven by a deep commitment to scientific excellence, and by the desire to bring innovative therapies to patients. Draupnir Bio is a spin out from Aarhus University and the Max-Planck Society based on the breakthrough scientific findings of Professors Simon Glerup, Camilla Gustafsen, Peder Søndergaard Madsen, and Peter Seeberger. Draupnir Bio expands research operations with new R&D facility at INCUBA research park. Draupnir Bio funded by a 30 M EUR series A investment by Novo Seeds, Gilde Healthcare Partners, INKEF Capital and High-Tech Gründerfonds. Draupnir Bio founded with investment from founders and grant from the Novo Nordisk Foundation.
+
Featured
Draupnir Bio
... Our Chief Scientific Officer Simon Glerup will present our small molecule platform for targeted degradation of extracellular proteins at the 1st Annual Targeted Protein Degradation for CNS Summit. ...
London, United Kingdom
1-10 Employees
As the industry consolidates pipelines and heads out of a turbulent 2023 market, the targeted protein degradation engine has shown no signs of slowing. Our blossoming community of degrader experts are inspiring each other to develop medicines to address patients’ unmet medical needs. Dedicated to Progressing the Field with Groundbreaking Research.
+
Featured
4th Targeted Protein Degradation Summit Europe - About
... The 4th TPD Summit Europe returns as Europe’s definitive meeting for uniting Targeted Protein Degradation professionals within Europe. ...
San Francisco, United States
101-250 Employees
2012
Our goal is to empower the body to fight disease using small molecule drugs to activate or inhibit the natural process of protein degradation. We are committed to the highest level of scientific inquiry and integrity. Nurix is committed to bringing novel, first-in-class therapies to patients without adequate treatment options. Nurix was founded by a team of internationally renowned experts in the fields of E3 ubiquitin ligase regulation and structure. Since its incorporation, Nurix has built a seasoned team of leaders with wide-ranging backgrounds in small molecule drug development and cancer therapy. Phelps has more than 10 years of experience in small molecule discovery, with a focus on DNA encoded library technology. Benson has over 22 years of experience in drug development across numerous indications and has worked on five drugs that have received FDA approval. Demirhan brings over 17 years of experience in drug pharmaceuticals and biotechnology, championing data-driven drug development ideology and implementation.
+
Featured
Targeted Protein Degradation
... Targeted Protein Degradation (TPD): A New Generation of Therapeutics Drugging the Undruggable E3 ligases catalyze the transfer of ubiquitin onto a target protein. The presence of the ubiquitin tag destines the protein for destruction by the proteasome. Targeted Protein Degraders are small ...
San Diego, United States
11-50 Employees
2019
To that end, we are advancing an undisclosed discovery pipeline of novel LYTAC degraders toward the clinic. We are also eligible to receive over $1.6 billion in potential milestone payments based on the achievement of prespecified preclinical, development and commercial milestones, as well as tiered royalties from mid-single to low double-digits on sales resulting from the agreement. We are leveraging the flexibility of our platform to pursue targets previously considered undruggable, opening the potential for new therapeutics options for patients. We are building a stellar team, driven to pioneer breakthrough science and motivated to make a difference for patients. Protein degradation offers the potential to eliminate disease-causing proteins. The mannose-6-phosphate receptor (M6PR) is a cell-surface glycoprotein that acts as a lysosomal trafficking shuttle.
+
Featured
Harnessing the Power of Protein Degradation for the Extracellular Proteome
... Harnessing the Power of Protein Degradation for the Extracellular ...
Malvern, United States
101-250 Employees
2001
Across all of our services, we consistently deliver high quality data, innovative solutions for custom-tailored projects, collaboration with scientists, and the flexibility you need to take your drug discovery program from target research to preclinical candidate and beyond. Our goal is the creation of potent drug candidates to meet the needs of tomorrow’s cancer patients. The Reaction Biology Platform offers a broad portfolio of services and a global network of partners that enable us to provide end-to-end service for the discovery of new small molecule and large molecule therapeutics. Reaction Biology brings over 20 years of experience supporting the development of new small molecules and large molecule therapies. We offer a broad portfolio of services that can provide end-to-end solutions for drug discovery, combined with an agile science-focused culture that delivers the same high quality of data for projects of any size. Reaction Biology offers one of the largest portfolio of kinase assays in the industry to support discovery of new kinase inhibitors. Reaction Biology offers a comprehensive portfolio of RAS assay services to support discovery of new RAS inhibitors. Reaction Biology's comprehensive portfolio of in vitro immuno-oncology assays and in vivo tumor models provides scientists with various platforms to test new cancer drug candidate's potency and efficacy.
+
Featured
Protein Degradation Assay - PROTAC Screening
... Protein Degradation Assays - PROTAC Screening | Reaction ...
Minneapolis, United States
1001-5000 Employees
1981
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for OEM and clinical customers. Bio-Techne’s genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand, as well as a portfolio of clinical molecular diagnostic oncology assays including the ExoDx® Prostate test (EPI) for prostate cancer diagnosis.
+
Featured
Custom Targeted Protein Degradation Services
... Explore custom targeted protein degradation services available from Bio-Teche such as PROTAC® panel builders, custom E3 ligases and degrader building blocks. ...
United States
11-50 Employees
2018
Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class medicines for the treatment of diseases lacking effective therapeutic approaches. Our mission is to utilize our revolutionary and proprietary targeted protein degradation technology to create new drugs for the treatment of diseases that currently lack effective therapies. CULLGEN ANNOUNCES ADDITIONS TO BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD. CULLGEN AND ASTELLAS HONORED WITH 2023 LES DEALS OF DISTINCTION AWARD.
+
Featured
Technology — Cullgen
... ™ Cullgen’s Protein Degradation ...
Technologies which have been searched by others and may be interesting for you:
Some interesting numbers and facts about the results you have just received for Protein Degradation
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 47 |
| Amount of suitable service providers | 27 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1981 |
| Youngest suiting company | 2022 |
Protein degradation is a critical biological process involving the breakdown of proteins within a cell through enzymatic mechanisms. This process is essential for maintaining cellular homeostasis by removing misfolded, damaged, or surplus proteins that could otherwise accumulate and cause cellular dysfunction. The ubiquitin-proteasome system (UPS) and lysosomal autophagy are the primary pathways facilitating protein degradation. The UPS tags defective or unneeded proteins with ubiquitin molecules, signaling their destruction by the proteasome, a complex protein-degrading machinery. Autophagy, on the other hand, engulfs and transports cellular debris, including proteins, to the lysosome for degradation and recycling. Protein degradation plays a pivotal role in various biological functions, including cell cycle regulation, signal transduction, and immune responses. Its dysregulation is associated with numerous diseases, such as neurodegenerative disorders, cancer, and metabolic syndromes, highlighting its significance in health and disease. Consequently, understanding protein degradation mechanisms has become a focal point of research, offering potential therapeutic targets for drug development aimed at modulating this process in disease conditions. Through the strategic manipulation of protein degradation pathways, researchers aspire to design innovative treatments that can specifically degrade pathological proteins, thereby offering new hope in the battle against complex diseases.
1. Targeted Action
Protein degradation offers highly targeted action against diseased cells without affecting the healthy ones. This specificity significantly reduces the risk of side effects compared to broader-acting alternatives, making it a safer option for patients.
2. Overcoming Drug Resistance
It presents a unique advantage in overcoming drug resistance, a common challenge with traditional treatments. By degrading the proteins that contribute to resistance mechanisms, it ensures that therapies remain effective over longer periods.
3. Versatility
This approach is versatile, capable of targeting a wide range of proteins, including those previously considered 'undruggable.' This opens new avenues for treating various diseases that lack effective interventions.
4. Durability of Response
Due to its mechanism of action, protein degradation often results in a more durable therapeutic response. By eliminating the problematic proteins rather than merely inhibiting their activity, it ensures longer-lasting relief from disease symptoms.
While evaluating the different suppliers make sure to check the following criteria:
1. Expertise in Protein Degradation
Ensure the supplier has a proven track record and specialized knowledge in protein degradation, including experience with various degradation technologies such as PROTACs, LYTACs, or molecular glue degraders.
2. Quality Control and Assurance
Verify the supplier’s quality control processes and whether they adhere to relevant industry standards. High-quality and consistent products are crucial for successful protein degradation research and applications.
3. Product Range and Availability
Assess the range of products offered related to protein degradation. A supplier with a broad selection can be a valuable resource for diverse research needs.
4. Technical Support and Service
Consider the level of technical support provided. Suppliers with knowledgeable and responsive support teams can significantly aid in the success of your projects.
5. Customization and Collaboration Opportunities
Check if the supplier offers customization options or collaborative opportunities for your specific protein degradation projects. This flexibility can be particularly beneficial for innovative or complex research.
In the pharmaceutical industry, protein degradation plays a pivotal role in drug discovery and development. Companies leverage this process to design targeted therapies that can selectively degrade harmful proteins associated with diseases. This method offers a more precise approach compared to traditional drugs, potentially leading to treatments with fewer side effects. The agricultural sector also finds valuable applications for protein degradation. Here, it's utilized to develop more resilient crops by manipulating the proteins responsible for stress responses. This innovation enables crops to better withstand harsh conditions such as drought or pest infestation, thereby enhancing yield and sustainability. In the field of biotechnology, protein degradation technologies are employed for waste management and recycling. Companies specializing in environmental sustainability use these processes to decompose organic waste into simpler, non-polluting substances. This application not only reduces waste but also contributes to the production of biofuels and other renewable resources, aligning with global efforts towards a greener economy. Lastly, in the cosmetics industry, understanding and applying protein degradation mechanisms can lead to the development of advanced skincare products. By targeting specific skin proteins, companies can create products that more effectively combat signs of aging, such as wrinkles and loss of elasticity, offering consumers more potent anti-aging solutions.
Protein degradation technology, pivotal in therapeutic applications and drug discovery, currently hovers around TRL 4 to TRL 5. This assessment is grounded in the technology's progression from initial validation in laboratory settings (TRL 4) to early-stage demonstration in relevant environments (TRL 5). At this stage, the technology has seen successful lab-scale experiments that confirm the mechanisms of targeted protein degradation, including the utilization of proteolysis targeting chimeras (PROTACs) and molecular glues. These methodologies have showcased the ability to selectively degrade pathological proteins, a breakthrough in treating diseases with previously "undruggable" targets. However, the transition to higher TRLs is impeded by several technical challenges. These include the need for improved delivery mechanisms to ensure the stability and bioavailability of degraders within the human body, the optimization of degradation tags to enhance selectivity and minimize off-target effects, and the comprehensive understanding of protein degradation pathways to predict therapeutic outcomes accurately. These hurdles necessitate further development and validation through clinical trials to confirm efficacy and safety profiles, moving protein degradation technologies towards full-scale application and commercialization.
In the Short-Term, advancements in protein degradation technology are poised to significantly enhance drug discovery processes. With the integration of high-throughput screening methods, researchers will be able to rapidly identify degrader molecules with high specificity and potency. This phase is expected to yield a new class of targeted therapeutics, particularly for diseases that have been challenging to treat with traditional drugs. Moving into the Mid-Term, the focus will shift towards optimizing the delivery mechanisms of protein degraders. Innovations in nanoparticle delivery systems and biohybrid materials will improve the stability and bioavailability of these molecules within the human body. This period will mark a crucial step in overcoming one of the main hurdles in the field, enabling more efficient targeting of disease-causing proteins without affecting the normal protein synthesis in healthy cells. In the Long-Term, the horizon broadens to the application of artificial intelligence and machine learning in refining protein degradation technologies. These tools will predict protein behavior more accurately, leading to the design of degraders that can target previously undruggable proteins. This advancement promises to revolutionize treatment modalities for a wide range of diseases, including those with genetic components, by providing highly personalized and effective therapy options.
